The NOV-ERA Phase 2b initiation de-risks the program modestly but top-line data is at least 12-18 months away. The €7M milestone is a known liability and not a surprise. Monitor enrollment updates and any interim data readouts; the primary endpoint at Week 24 is the next major catalyst. Historical stock performance on prior clinical milestones has been poor, suggesting limited near-term upside from this event alone.
Price Chart
Executive Summary
Agomab announced the first patient dosed in the global NOV-ERA Phase 2b study of ontunisertib for fibrostenosing Crohn's disease, a milestone that triggers a €7 million milestone payment to former Origo Biopharma shareholders. The study will enroll ~320 patients across three dose levels vs placebo, with top-line data at Week 24 primary endpoint.
Key Facts
- First patient dosed in NOV-ERA Phase 2b study of ontunisertib (AGMB-129) for fibrostenosing Crohn's disease
- Study to enroll approximately 320 patients globally across 3 dose levels (400mg, 200mg, 100mg BID) and placebo
- Primary endpoint: proportion of patients achieving endoscopic passability at Week 24
- Study initiation triggers a €7 million milestone payment to former Origo Biopharma shareholders
- Total milestone payments under 2021 Origo acquisition: up to €20 million; €10 million now payable including €3 million paid in 2025
- Ontunisertib has U.S. FDA Fast Track Designation
- Phase 2a STENOVA results and positive long-term safety/tolerability OLE data support the Phase 2b design
Financial Impact
€7 million milestone payment triggered; total potential milestone payments up to €20 million under the 2021 Origo acquisition
Risk Factors
- Phase 2b may fail to meet primary endpoint (endoscopic passability at Week 24)
- Enrollment delays or safety signals could emerge during the 52-week treatment period
- No approved therapies for FSCD exist, making regulatory path uncertain
- Cash burn from Phase 2b may require future financing; no revenue to offset costs
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-115567 |
| Document: tm2627540d1_6k.htm | 0001104659-26-115567 |
| Document: 0001104659-26-115567-index-headers.html | 0001104659-26-115567 |
| Document: 0001104659-26-115567-index.html | 0001104659-26-115567 |
| Document: 0001104659-26-115567.txt | 0001104659-26-115567 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Insider Buy | $9.26 | awaiting T+5 | — | $8.40 (−9.29%) |
Oct 13, 2026 13d ago | 6-K | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.40 (−3.34%) |
Oct 13, 2026 14d ago | Press Release | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $8.40 (−3.34%) |
Oct 1, 2026 26d ago | 6-K | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.40 (−2.89%) |
Oct 1, 2026 26d ago | Press Release | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $8.40 (−2.89%) |
Sep 14, 2026 6w ago | 6-K | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.40 (−30.92%) |
Sep 14, 2026 6w ago | Press Release | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $8.40 (−30.92%) |
Sep 11, 2026 6w ago | 6-K | $12.28 $11.70 | ▼ −4.72% | ▼ −4.83% | $8.40 (−31.60%) |
Aug 10, 2026 11w ago | 6-K | $14.85 $13.73 | ▼ −7.54% | ▼ −7.14% | $8.40 (−43.43%) |
Jun 23, 2026 17w ago | 6-K | $12.68 $11.87 | ▼ −6.39% | ▼ −8.10% | $8.40 (−33.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers